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Objective. Cervical cancer screening by surveys overestimate coverage because of selection and reporting
biases.
Methods. The prepared Inter-Mutualistic Agency dataset has about 13 million records from Pap smears,
colposcopies, cervical biopsies and surgery, performed in Belgium between 1996 and 2000. Cervical cancer
screening coverage was deﬁned as the proportion of the target population (women of 25–64 years) that has
had a Pap smear taken within the last 3 years. Proportions and incidence rates were computed using ofﬁcial
population data of the corresponding age group, area and calendar year.
Results. Cervical cancer screening coverage, in the period 1998–2000, was 59% at national level, for the
target age group 25–64 years. Differenceswere small between the 3 regions. Variation ranged from 39% to 71%.
Coverage was 64% for 25–29 year old women, 67% for those aged 30–39 years, 56% for those aged 50–54. The
modal screening interval was 1 year. In the 3-year period 1998–2000, 3 million smears were taken from the
2.7millionwomen in the age group 25–64. Only 1.6millionwomen of the target group got one ormore smears
in that period and 1.1 million women had no smears, corresponding to an average of 1.88 smears per woman.
Conclusion. Coverage reached only 59%, but the number of smears used was sufﬁcient to cover more than
100% of the target population. Structural reduction of overuse and extension of coverage is warranted.
© 2009 Elsevier Inc. All rights reserved.IntroductionThe Belgian Cancer Registry (Belgian Cancer Registry Foundation,
2008) records yearly, approximately 650 to 700 cases of invasive
cervical cancer and between 290 and 370 women die from the disease
(Arbyn and Geys, 2002; Arbyn et al., 2007, in press-b). The burden of
cervical cancer in Belgium ranks at a central place among the member
states in the European Unionwith aworld-age standardized incidence
and mortality rate of 11 and 4/100 000 women-years, respectively
(Arbyn et al., 2007).
Through a well-organized cytological screening, the incidence of
cervical cancer can be reduced to a small residual level (IARC, 2005), as
was demonstrated two decades ago in four Nordic countries (Laara et
al., 1987) andmore recently in the United Kingdom (Quinn et al., 1999;
Peto et al., 2004), Norway (Nygard et al., 2002), and the Netherlands
(van der Aa et al., 2007). In Belgium, screening is essentially
opportunistic, which means that Pap smears are taken at thel rights reserved.
nalysis of 13 million individ
, 1996–2000). Prev. Med. (2spontaneous initiative of the woman, her gynecologist or her general
practitioner (Arbyn and Van Oyen, 2004; Arbyn et al., in press-a).
Opportunistic screening usually results in a high level of over-
screening and a heterogeneous quality (Miller, 2002; Arbyn et al., in
press-c). In spite of the large amount of Pap smears consumed yearly,
the impact on cervical cancermortalitywas lower than observed in the
organizedNordic countries (Arbyn et al., 2002; Arbyn andGeys, 2002).
The Belgian cervical cancer screening policy is adapted from the
European Guidelines and foresees one Pap smear or liquid-based
cytology sample every 3 years for women of 25 to 64 years of age
(Coleman et al., 1993; Council of the European Union, 2003; European
Commission, 2008). Nevertheless, the level of adherence to this policy
is rather poor, also in the Flemish provinces where in the mid 1990s, a
program was set up involving invitation of women in the target age
range 25–64 (Arbyn et al., in press-a).
Optimal attendance of the target population is one of the main
determinants of success of a screening program (Anttila et al., 2008).
Until recently, in Belgium, this attendance could only be assessed by
surveys (Arbyn et al., 1997; Arbyn and Van Oyen, 2000; Demarest et al.,
2002). Such surveys, involving collection of information directly fromual patient records pertaining to Pap smears, colposcopies, biopsies
009), doi:10.1016/j.ypmed.2009.02.021
Fig. 1. Variation of the screening coverage and the # smears/# women ratio considered
over a 3-year interval according to 5-year age group (Belgium, 2000).
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systematically result in overestimated coverage rates (Kottke et al.,
1995; Montano and Phillips, 1995). The current study aims to assess the
real cytological screening coverage as well as the consumption of
medical acts for screening and follow-up or treatment of screen positive
women. Therefore, a data ﬁle obtained from the Inter-Mutualistic
Agency (IMA),which pools information from all social health insurance
companies in Belgium (Arbyn and Van Oyen, 2004), was used.
Methods
A mandatory social health insurance system covers the whole
population, ofﬁcially residing in Belgium. This health insurance
system is mediated by “sickness funds” that register all reimbursed
contacts of their members with health services. The Inter-Mutualistic
Agency (IMA) compiles, for speciﬁc purposes, ﬁles from reimburse-
ment claims originating from the sickness funds. This generates a
virtually complete source of information on health services delivered
to patients, since over 99.5% of the Belgian resident population is
registered as having a health insurance. On demand of the Scientiﬁc
Institute of Public Health (Brussels, Belgium), a data ﬁle containing
more than 13 million individual patient records was compiled by IMA.
It contained information of all medical acts related to cervical
screening and diagnostic or therapeutic interventions on the uterine
cervix (Pap smear collection and interpretation, colposcopies, cervical
biopsies and their interpretation, surgery on the cervix) performed on
women resident in Belgium, between 1996 and 2000. The databaseTable 1
Consumption of Pap smears, associated costs (in euro), three-year screening coverage and




Flemish Region 1996–1998 1,582,128 1,569,687
1997–1999 1,585,642 1,639,685
1998–2000 1,587,847 1,691,932
Brussels 1996–1998 253,557 264,611
1997–1999 254,534 277,884
1998–2000 255,656 292,582
Walloon Region 1996–1998 867,361 944,176
1997–1999 870,296 983,611
1998–2000 873,429 1,010,866
Whole of Belgium 1996–1998 2,703,047 2,778,474
1997–1999 2,710,473 2,901,180
1998–2000 2,716,933 2,995,380
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and surgery on the uterine cervix (Belgium, 1996–2000). Prev. Med. (2involves medical acts performed in all types of medical services
(private physicians, group practices, private and public outpatient
clinics and hospitals). The data set didn't contain diagnostic or clinical
information.
A numerical individual ID code (to ensure privacy protection), age,
date of the act, residence of the woman, and type of the medical act
was provided in the data set. The ID code was a number which was
constant at the level of the individual woman, allowing tracing of
longitudinal histories. For all subjects, data details were truncated to
reduce the risk of obtaining unique data in the cells of cross tables. Age
was converted into ﬁve-year age groups at the exception of the group
0–14 and the 75+ age group, which were each grouped into one
category. The calendar date of the act was restricted to the year of
performance. The residence was converted into the district. The code
‘district=99’was reserved for Belgian insured women, not residing in
Belgium. Sometimes, district code=0 was used in case of rare
combinations to avoid identiﬁcation of women.
Statistical analyses
Datawere aggregated by age groups, by several geographical levels
(country, 3 regions [Flemish Region, Capital Region of Brussels, and
the Walloon Region], 11 provinces and 43 districts), and combined
with the respective mid-period population size (source: National
Institute of Statistics) to compute proportions or incidence rates.
Cervical cancer screening coverage was deﬁned as the proportion
of the target population (women of 25–64 years) that has had a Pap
smear taken within the last 3 years. Overuse (or excess use) was
deﬁned as the proportion of Pap smears taken in the target group that
does not contribute to the coverage (number of smears taken in 3-
years time/number of women screened in that period−1)⁎100.
For computation of cumulative incidence until a given age k, the







where Π stands for cumulative product, ai for age-speciﬁc




Cervical cancer screening coverage, measured in 2000, was 59%








870,520 55.0% 0.99 80.3%
900,538 56.8% 1.03 82.1%
911,761 57.4% 1.07 85.6%
134,397 53.0% 1.04 96.9%
141,204 55.5% 1.09 96.8%
147,381 57.6% 1.14 98.5%
506,947 58.4% 1.09 86.2%
522,153 60.0% 1.13 88.4%
532,113 60.9% 1.16 90.0%
1,511,864 55.9% 1.03 83.8%
1,563,895 57.7% 1.07 85.5%
1,591,255 58.6% 1.10 88.2%
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Fig. 2. Geographical variation of the screening coverage considered over a 3-year interval (Belgium, by District, 1998–2000, 25–64 years old women).
3M. Arbyn et al. / Preventive Medicine xxx (2009) xxx–xxx
ARTICLE IN PRESSthe Regions was small: 57% in the Flemish Region, 58% in Brussels
and 61% in the Walloon Region. The increase in coverage measured
over the period 1996–2000 was limited and respectively 2%, 5% and
3% in the Flemish, Brussels and Walloon Region (Table 1). This
limited increase in the Flemish Region was remarkable, given the
fact that in this region a screening campaign was organized. Diffe-
rences at lower geographical levels were substantial: at provincial
level, in 2000, screening coverage ranged from 52% (Luxembourg)
to 69% (Walloon-Brabant); whereas at district level the highest
coverage is found in Huy (71%) and the lowest in Arlon (only 39%)
(Fig. 2).
In the youngest 5-year age group of the target population,
women of 25–29 year old, the coverage was 64%, at the national
level. It increased until 67% among women in the age range 30–
39 years. From the age of 40, the coverage decreased gradually until
56% in the 50–54 year age group. Thereafter, the coverage declined
more rapidly (Fig. 1). In the Brussels and Walloon Region this
decline by age group was less pronounced.
Screening interval and screening beyond the target age range
For women contributing two or more smears, the screening
intervals were less than 1 year in 13%, 1 year in 61%, 2 years in 21%,Table 2
Number of colposcopies, cervical biopsies, and Pap smears; ratio of the number of biopsies o
colposcopies, and ratio of the number of biopsies over the number of Paps, Belgium, 1996–
Region Colposcopies Biopsies Pap smears
Flemish Region 618,033 53,825 3,003,722
Brussels 207,587 12,143 586,105
Walloon Region 1,176,139 39,315 2,128,873
Total 2,001,759 105,283 5,718,700
Please cite this article as: Arbyn, M., et al., Analysis of 13 million individ
and surgery on the uterine cervix (Belgium, 1996–2000). Prev. Med. (23 years in 5%, and 4 years or more in 1%. Ten percent of all interpreted
Pap smears were taken fromwomen younger than 25 years and 7% in
women older than 64 years. In younger women, the three-year
screening coverage was 16% and 49%, for the age groups 15–19 and
20–24, respectively. For older women, the coveragewas 27% in the age
group 65–69 and 18% in the age group 70–74.
Profession of smear takers
The large majority of smears were taken by gynecologists (85%).
The proportion of smears prepared by general practitioners (GPs) was
limited (15%) and varied substantially by Region: in 2000, in the
Flemish Region 20% was taken by GPs, whereas only 8% and 3% in
Brussels and the Walloon Region respectively. The trend of the
proportion of cervical samples collected by GPs was decreasing
between 1996 and 2000: −22%, −19%, and −27% in the Flemish,
Brussels, and Walloon Region, respectively.
Pap smear use
In 2000, the ratio of the number of Pap smear interpretations
over the size of the target population concerned was 1.1. This ratio
could have been higher if we would have been able to adjust thever the number of colposcopies, ratio of the number of Pap smears over the number of
2000.
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Fig. 3. Incidence of conization by age (left); cumulative incidence of conization up to a given age (right) in Belgium, 1996–2000.
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removed before 1996. In absolute ﬁgures: 3 million Pap smears were
interpreted in the period 1998–2000 which were taken from only
1.6 million women. One million and hundred thousand women,
accounting for 41% of the target group, did not get a Pap smear
during the study period. The excess use of cervical cytological
examinations was 88%, which means that each screened women
received on average 1.88 smears over a 3-year period. The excess
smear use was high in all parts of Belgium: 86% in the Flemish
Region, highest in the Capital Region (99%), and intermediate in the
Walloon Region (90%) (Table 1).
Colposcopy use
At the national level, on average, one colposcopic examinationwas
done for every 3 Pap smears. In the Flemish Region the ratio of the
number of Pap smears over the number of colposcopies was 4.9, in
Brussels 2.8, whereas for the Walloon Region this ratio was even less
than two (Table 2). In someWalloon districts the number of examined
Pap smears was equal to the number of performed colposcopies.
The biopsy/colposcopy ratio was low (on average 5%), due to the
very high frequency of colposcopy in cervical lesion free women
(Table 2).
Conizations
Fig. 3 displays the incidence of conization (including large loop
excision of the transformation zone (LLETZ)) by age, as well as the
cumulative incidence up to a given age. Only ﬁrst conizations were
taken into account. The peak incidencewas noted in the age group 30–
34 years (2.0/1000 women-years). Up to the age of 34 years, 2.5% of
women have had a history of conization.Fig. 4. Incidence of total hysterectomy by age (left); cumulative incidence o
Please cite this article as: Arbyn, M., et al., Analysis of 13 million individ
and surgery on the uterine cervix (Belgium, 1996–2000). Prev. Med. (2Hysterectomies
Fig. 4 displays the incidence of total hysterectomy by age, and the
cumulative incidence up to a given age. The incidence of hysterectomy
was highest in the age range 40–54 years: 8.2, 9.6, and 7.3 per 1000
women-years in age groups 40–44, 45–49, and 50–54 years, respec-
tively. Up to the age of 49 years, 14.8% of women were hysterecto-
mized. The shape of the curve was similar for the three regions as
described for the whole of Belgium. However, the age-speciﬁc
incidences were substantially higher in the Flemish Region and
substantially lower in Brussels, compared to the national average.
Peak incidences, in the 45–49 year age group were 10.6, 6.4, and 8.7
per 1000 women-years in the Flemish, Brussels Capital and Walloon
Region, respectively.
Twenty ﬁve percent of women of 20 years or older, hysterecto-
mized in 1997, had at least one Pap smear taken in the subsequent
3 years.
Discussion
The large exhaustive data ﬁle containing more than 13 million
individual records compiled from reimbursement claims has, for
the ﬁrst time, enabled us to compute with high precision, the
volume of performed medical acts that pertain to cervical cancer
prevention.
Screening coverage, amount and cost of over-screening
Only 59% of women in the age range 25–64 years had received a
Pap smear in the last 3 years. However, the amount of smears taken
should be sufﬁcient to cover the whole target population. Indeed,
assuming that 10% of the non-screening smears were spent for repeatf total hysterectomy up to a given age (right) in Belgium, 1996–2000.
ual patient records pertaining to Pap smears, colposcopies, biopsies
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specimen, for follow-up after negative colposcopy or after treatment
of cervical lesions, we estimate that yearly about 400,000 Paps were
taken that did not contribute to screening coverage or follow-up, for
an estimated yearly budget of € 8.2million reimbursed by the National
Health Insurance Institute. This amount is further increased by €
3.9 million for screening performed beyond the target age range.
Moreover, the costs for consultation by a gynecologist or GP were not
taken into account in our analysis.
Most smears are taken by gynecologists. In theWalloon Region, the
gynecologist is almost the exclusive smear taker. In a telephone survey
conducted in the Flemish Region, in 1996, screened women indicated
their gynecologist as the preferred smear taker, whereas non-
screened women would accept the proposal of a GP to have a Pap
smear taken (Arbyn et al., 1997). These data show that GPs have a role
to play in reaching non-covered women.
The coverage computed from the individual health insurance data
ﬁle was substantially lower than the estimates derived from the
national health interview surveys. For instance at national level, for
the year 2000, this difference was 11% (Demarest et al., 2002; Arbyn
and Van Oyen, 2004). This discrepancy is probably due to reporting
biases, which appear to be inherent to interview surveys (Walter et al.,
1988; McKenna et al., 1992; Fruchter et al., 1992; Kottke et al., 1995;
Montano and Phillips, 1995). Therefore, estimations of the screening
coverage, derived from interview surveys should be interpreted with
caution.
Colposcopies
An impressive amount of colposcopies are performed in Belgium.
Colposcopy is often performed simultaneously to the Pap smear,
whereas its main clinical indication is the exploration of women
with previous cytological abnormality. It is clear that colposcopy
was not used according to accepted national or international
guidelines, considered in the study period (Kurman et al., 1994;
Arbyn et al., 1996). In that period, colposcopic exploration was
indicated in case of a ﬁrst observation of HSIL (high-grade
squamous intra-epithelial lesion) or glandular abnormality or after
a second observation of ASCUS (atypiscal squamous cell of under-
mined signiﬁcance) or LSIL (low-grade squamous intra-epithelial
lesions). The prevalence of these lesions, estimated from reports
received from laboratories in two Flemish provinces, was: 0.5% for
HSIL, 1% for LSIL, 2% for ASCUS and 0.1% for atypical glandular cells
(Arbyn et al., 1999a).
Health authorities and representatives of scientiﬁc societies should
discuss as soon as possible on how to reduce the amount of
colposcopies performed, the revalidation of its cost price, and the
introduction of procedures of quality assurance.
Conizations
Over-consumption of screen tests, inevitably generates unneces-
sary follow-up examinations (repeat Pap smears, colposcopies,
biopsies) and treatment of lesions. Recent meta-analytical work has
indicated that excisional treatment of cervical intra-epithelial neo-
plasia (CIN) is associated with adverse obstetrical outcomes (Kyrgiou
et al., 2006; Arbyn et al., 2008). Currently, LLETZ is themost frequently
used procedure to treat CIN in Belgium as well as in other
industrialized countries (Jordan et al., 2008; Wright et al., 2007). On
average, pregnant women previously treated with LLETZ have a risk of
preterm delivery (PD) that is 1.70 (95% CI: 1.24–2.35) times higher
than for non-treated pregnant women (Kyrgiou et al., 2006). Taking
into account, the maternal age distribution at delivery (Centre for
Operational Research in Public Health, 2006), and the cumulative
incidence of conization over age (Fig. 3b), we can estimate that 2%
(95% CI: 0.7–3.6%) of all PDs in Belgium are attributable to prior LLETZ.Please cite this article as: Arbyn, M., et al., Analysis of 13 million individ
and surgery on the uterine cervix (Belgium, 1996–2000). Prev. Med. (2However, among treatedwomen, the risk of PD attributable to LLETZ is
about 41% (95% CI: 19–57%).
Hysterectomies
Women who have undergone total hysterectomy are not at risk
for cervical cancer if the indication for the intervention was not
oncologic. These women could be excluded from the target popu-
lation for cervical cancer screening. However, 25% of women hyste-
rectomized in 1997, had at least one Pap smear taken in the
subsequent 3 years. From other sources, it was estimated that 13% of
total hysterectomies in Belgium are performed for a malignant
indication (Mertens, 1999), so these women can be considered as
still requiring cytological testing. Unfortunately, the data provided by
IMA do not provide the indication of the hysterectomy. In a recent
survey in the United States, it was noted that 64% of hysterectomized
women were still cytologically screened (Sirovich and Welch, 2004).
In Belgium, over-screening in women without cervix is dramatically
lower.
Study limitations
The identities of the respective women were encoded to ensure
protection of privacy. Nevertheless, records can refer to a unique
person by their content when locality, age and date of the medical act
are known. So, truncation of datawas done to reduce the probability of
providing unique data, which theoretically includes a risk of
identiﬁability.
This impeded computation of precise screening intervals and
excluded the possibility to assess the exact delay between (or the
simultaneity of) Pap smear collection and other investigations or
interventions.
The received data contained only administrative content and were
not linkable with medical registries. It must be remarked that
organized population screening, includes by deﬁnition registration
of individual data with the possibility of linkage between population-,
screening-, cancer- and mortality-registers (Council of the European
Union, 2003; Commission of the European Communities, 2003).
Moreover the Belgian privacy protection law foresees derogation
speciﬁcally for population screening (Arbyn et al., 1999b).
Conclusions
The collected study material constitutes an enormous resource for
epidemiological research and program evaluation. It reveals sub-
stantial overconsumption of resources with limited health beneﬁts.
The coverage reached only 59%, but the number of smears taken was
sufﬁcient to cover more than 100% of the target population. Organized
screening, involving a structural reduction of overuse and re-
investment in coverage and quality improvement, could potentially
result in more life-years saved, without increase in public funding.
Introduction of new methods, such as screening for oncogenic HPV
(human papillomavirus) types and prophylactic HPV vaccination
allowing screening at wider intervals and less aggressivemanagement
algorithms, a fortiori will require a well-organized screening system.
Furthermore, public funding should be based upon evidence based
recommendations, as described in the European Guidelines for
cervical cancer screening.
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